Emily J. Cook

Subscribe to Emily J. Cook's Posts
In today’s complex and fast-changing healthcare regulatory environment, Emily Jane Cook helps healthcare organizations thrive. Innovative start-ups and established market leaders alike turn to Emily for broad-spectrum strategies to fuel new business initiatives and solve their most pressing compliance, transactional, reimbursement and litigation challenges. Emily is a practice area leader for the Healthcare Regulatory & Compliance practice. In addition to Emily’s role as a national authority on the 340B drug pricing program, Emily helps clients navigate the full suite of federal and state regulations that are essential to healthcare operations. She partners with a wide range of organizations, including non-traditional service providers and new market entrants to identify, protect and expand revenue opportunities, including via private-equity-backed ventures. Her comprehensive counsel encompasses evolving issues such as No Surprises Act (NSA) implementation, development of new provider types, Medicare provider-based and co-location rules, and trends in qui tam litigation and government investigations. She works closely with colleagues in McDermott’s transactional, litigation and private equity practices to deliver fully realized solutions for her clients. Read Emily Cook's full bio.

CMS Proposes Heightened Penalties and Additional Requirements Under the Hospital Price Transparency Rule


By and on Sep 28, 2021
Posted In Employee Benefits, Health and Welfare Plans

On July 19, 2021, US President Joe Biden’s administration released a proposed rule that would increase penalties for hospitals that do not comply with the Hospital Price Transparency Rule, effective January 1, 2022. According to McDermott’s Emily Jane Cook and Steven J. Schnelle, the proposed rule also provides certain potentially burdensome clarifications and requests comment...

Continue Reading



Drug Prices Are Prime Target in Biden’s Competition Order


By on Jul 14, 2021
Posted In Employee Benefits, Health and Welfare Plans

President Biden’s July 9, 2021, Executive Order—which seeks to increase competition throughout the American economy—takes aim at prescription drug prices. In this article, published in Law360, McDermott partner Emily Jane Cook says Biden’s focus on drug prices is unsurprising given the “significant public interest and frustration” with drug costs. Access the article.

Continue Reading



Drug Discount Fights in Limbo Until Biden Restores Review Board


By on May 26, 2021
Posted In Employee Benefits, Health and Welfare Plans

McDermott Will & Emery lawyer Emily J. Cook recently spoke to Bloomberg Law about a drug alternative dispute resolution (ADR) process that’s on hold after the Biden administration removed its Trump administration appointees. This particular process concerns Department of Health and Human Services panelists that will determine the direction of a 340B drug review board....

Continue Reading



Court Issues Permanent Injunction Blocking Medicare 340B Payment Cuts


By , , and on Jan 22, 2019
Posted In Employee Benefits, Health and Welfare Plans

The US District Court for the District of Columbia recently held that the Centers for Medicare and Medicaid Services (CMS) exceeded its authority by reducing Medicare payment rates for 340B drugs, but, because of the budget-neutral nature of the cuts, the court left implementation details of its order temporarily unresolved to avoid disrupting administration of...

Continue Reading



STAY CONNECTED

TOPICS

ARCHIVES

Top ranked chambers 2022
US leading firm 2022